Organon rises as review finds no issues in past biosimilar purchases

Shares of healthcare firm Organon OGN.N rise 3.5% to $7.78 premarket

Co says an independent review found no wrongdoing in how it recorded earlier purchases of biosimilars, which are lower‑cost versions of complex biologic drugs

 Co says its board audit committee launched the review after concerns were raised about timing of past biosimilar purchases; review found no need to revise past SEC filings

Co says the annual report for 2025 will be filed on time

Shares down ~52% in 2025